



VGX announced key management team promotions and additions

Blue Bell, PA – August 1, 2005 – J. Joseph Kim, Ph.D., President and Chief Executive Officer of VGX Pharmaceuticals today announced several key management changes and appointments designed to expand the organization as it continues to meet important milestones.

Ernest Shin, Chief Operating Officer

Ernest E. Shin has been promoted to the position of Chief Operating Officer. Mr. Shin joined VGX in 2001 as its second employee. Since that time he has played a significant role in helping Dr. Kim, a co-founder of VGX, to create, establish and develop the company.

Mr. Shin began his professional career at the Naval Air Warfare Center Aircraft Division as an Aerospace Engineer and later went on to found and operate a number of startup operations. He has also served in a variety of senior finance and management positions in several high tech and pharmaceutical companies, including Hoffman La-Roche. In these various roles, he developed comprehensive corporate strategies dealing with operational, marketing and financial issues.

Mr. Shin received his Bachelor of Science degree in Mechanical/Aerospace Engineering from Rutgers College of Engineering and his MBA in Finance and Entrepreneurial Management from the Wharton School.

C. Jo White, M.D., Chief Medical Officer

Dr. White has 18 years of senior level clinical/medical affairs positions with major pharmaceutical companies including BMS, Wyeth and Merck. Her experience has been focused in the area of infectious diseases and she is trained as an Internist and Infectious Disease specialist. Dr. White has designed and conducted over 40 Phase 1-4 trials, filed several Biologics License Applications/Marketing Authorization Applications and has obtained regulatory approval for 5 different vaccines and drugs in both the United States and Europe.

Dr. White was trained in Microbiology at University of Texas where she graduated Summa Cum Laude. Dr. White also holds an M.D. from the Baylor College of Medicine with Alpha Omega Alpha honors.

Bryan B.J. Kim, D.M.D., Director, Corporate Development

Dr. B. J. Kim, D.M.D. has been named Director, Corporate Development. Dr. Kim has over 8 years of experience as a successful private clinician and is a respected teacher/researcher.

In addition to his responsibilities with VGX Dr. Kim is also a Clinical Assistant Professor at University of Pennsylvania, School of Dental Medicine where he has developed innovative clinical programs and directed important research projects granted by NIDH in microbiology and immunology.

Dr. Kim holds a Bachelor of Arts degree in Economics and a Bachelor of Science degree in Biological Science, both from University of California at Irvine. He also holds a Doctor of Dental Medicine degree from the University of Pennsylvania.

Robert J. Juba, Director, Manufacturing and Quality

Robert J. Juba has been appointed Director, Manufacturing and Quality. Mr. Juba has 11 years of experience in the pharmaceutical industry at Merck & Co. He has managed several contract manufacturing and filling projects for developmental products (Vaccines for Rotavirus and HIV-1), led pilot plant operations for research and clinical supply manufacturing, and provided technical expertise for bacterial vaccine manufacturing. He has extensive experience in managing cGMP processes and operations.

Mr. Juba holds both Bachelor's and Master's Degrees in Chemical Engineering from the Massachusetts Institute of Technology.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with product candidates for the treatment of infectious diseases including HIV, hepatitis C as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic hepatitis C virus infection. In addition, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic with novel product candidates to treat cancer and inflammatory diseases. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Vice President

Tel 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com